Marksans Pharma Ltd.
NSE: MARKSANS | BSE: 524404
₹252.75
₹16.69
(7.07%)
As on 09-Jun-2026IST
Market cap
₹11,445 Cr
Revenue (TTM)
₹2,951 Cr
P/E Ratio
27.4
P/B Ratio
3.8
Div. Yield
0.4 %
Quality Score
7/10
Growth Score
6/10
Valuation Score
4/10
Momentum Score
8/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹418 Cr
-
ROE
16.9 %
-
ROCE
22.5 %
-
Industry P/E
--
-
EV/EBITDA
15.3
-
Debt to Equity
0
-
Book Value
₹66.7
-
EPS
₹9.2
-
Face value
1
-
Shares outstanding
453,163,746
10 Years Aggregate
CFO
₹1,308.01 Cr
EBITDA
₹2,493.13 Cr
Net Profit
₹1,719.25 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Marksans Pharma
| 40.2 | 27.8 | 47.8 | 0.3 | 42.7 | 29.6 | 19.3 |
|
BSE Healthcare
| 8.7 | 1.4 | 8.4 | 9.2 | 24.9 | 13.5 | 12.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Marksans Pharma
| -40.8 | 84.7 | 176.6 | -3.2 | -1.3 | 253.6 | -40.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Marksans Pharma
|
252.8 | 11,444.7 | 2,950.9 | 420.1 | 17.0 | 14.6 | 27.4 | 3.8 |
| 187.9 | 2,957.7 | 2,931.9 | 97.5 | 7.7 | 1.5 | 30.4 | 0.4 | |
| 145.0 | 645.2 | 410.8 | 38.0 | 7.2 | 11.9 | 16.8 | 1.5 | |
| 523.4 | 12,643.7 | 3,510.5 | 401.1 | 14.0 | 13.9 | 31.5 | 4.0 | |
| 70.1 | 249.2 | 128.4 | -10.4 | -9.4 | -10.4 | -- | 2.7 | |
| 21.7 | 654.0 | 1,449.5 | 55.0 | 6.8 | 11 | 12.6 | 1.3 | |
| 1,229.7 | 26,090.2 | 2,192.5 | 348.9 | 21.2 | 14.9 | 74.8 | 10.5 | |
| 4,713.3 | 10,813.0 | 935.0 | 257.9 | 34.3 | 78.9 | 41.9 | 23.9 | |
| 29.6 | 440.1 | 54.2 | 10.9 | -4.1 | 13.9 | 40.6 | 14.2 | |
| 24.5 | 53.8 | 53.3 | -1.7 | 20.3 | -14.9 | -- | 0.6 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Marksans Pharma
Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic... hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India. Read more
-
Incorporated
1992
-
Chairman
Mark Saldanha
-
Managing Director
Mark Saldanha
-
Headquarters
Mumbai, Maharashtra
-
Website
Looking for more details about Marksans Pharma Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
Announcements
View AnnouncementsCorporate Action-Board approves Dividend
26-May-2026No News & Announcements are available.
FAQs for Marksans Pharma
What is the current share price of Marksans Pharma Ltd Today?
The share price of Marksans Pharma Ltd is ₹252.75 (NSE) and ₹248.90 (BSE) as of 09-Jun-2026 IST. Marksans Pharma Ltd has given a return of 42.74% in the last 3 years.
What is the current PB & PE ratio of Marksans Pharma Ltd?
The P/E ratio of Marksans Pharma Ltd is 27.39 times as on 09-Jun-2026.
The P/B ratio of Marksans Pharma Ltd is 3.79 times as on 09-Jun-2026, a 781 premium to its peers’ median range of 0.43 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
26.48
|
4.08
|
|
2024
|
21.89
|
3.33
|
|
2023
|
11.99
|
1.83
|
|
2022
|
10.10
|
1.68
|
|
2021
|
8.67
|
2.31
|
What is the 52 Week High and Low of Marksans Pharma Ltd?
The 52-week high and low of Marksans Pharma Ltd are Rs 270.70 and Rs 155.00 as of 09-Jun-2026.
What is the market cap of Marksans Pharma Ltd?
Marksans Pharma Ltd has a market capitalisation of ₹ 11,445 Cr as on 09-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Marksans Pharma Ltd?
Before investing in Marksans Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.